Radius Recycling, Inc. (RDUS)
(Real Time Quote from BATS)
$17.58 USD
+0.03 (0.17%)
Updated May 3, 2024 10:32 AM ET
4-Sell of 5 4
A Value B Growth B Momentum A VGM
Brokerage Reports
[RDUS]
Reports for Purchase
Showing records 21 - 40 ( 169 total )
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Tymlos Patch Fizzles in Phase 3 Miss While EMERALD Data Shines at SABCS 2021; Reiterate Neutral, PT Down to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Disappointing Sales But Male sNDA and Transdermal Patch Could Expand Opportunity; Reiterate Neutral, PT Down to $23
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Drugs
Positive Top Line in Registrational Breast Cancer Study for Elacestrant
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Drugs
Tymlos Hits Primary Endpoint in Male Osteoporosis Phase 3 and More Catalysts on the Horizon
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
It Takes Time to Refill the Patient Queue; Reiterate Neutral, Price Target Down to $19
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
RAD011 Development for Prader-Willi Syndrome Comes into Focus Under 505(b)(2); Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Tymlos Hits a Speedbump in 1Q, But We See Plenty of Runway; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department